Tìm theo
Zafirlukast
Các tên gọi khác (4 ) :
  • 4-(5-Cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-O-tolylsulfonylbenzamide
  • Accolate
  • Cyclopentyl 3-(2-methoxy-4-((O-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate
  • ICI-204,219
Thuốc chữa hen và bệnh phổi tắc nghẽn mãn tính
Thuốc Gốc
Small Molecule
CAS: 107753-78-6
ATC: R03DC01
ĐG : AstraZeneca Inc. , http://www.astrazeneca.ca
CTHH: C31H33N3O6S
PTK: 575.675
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C31H33N3O6S
Phân tử khối
575.675
Monoisotopic mass
575.209006493
InChI
InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
InChI Key
InChIKey=YEEZWCHGZNKEEK-UHFFFAOYSA-N
IUPAC Name
cyclopentyl N-{3-[(2-methoxy-4-{[(2-methylbenzene)sulfonyl]carbamoyl}phenyl)methyl]-1-methyl-1H-indol-5-yl}carbamate
Traditional IUPAC Name
cyclopentyl N-[3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)-1-methylindol-5-yl]carbamate
SMILES
COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=CC=CC=C1C
Độ tan chảy
139 °C
Độ hòa tan
9.62e-04 g/l
logP
5.4
logS
-5.8
pKa (strongest acidic)
4.29
pKa (Strongest Basic)
-1.1
PSA
115.73 Å2
Refractivity
158.58 m3·mol-1
Polarizability
62.06 Å3
Rotatable Bond Count
8
H Bond Acceptor Count
6
H Bond Donor Count
2
Physiological Charge
-1
Number of Rings
5
Bioavailability
0
MDDR-Like Rule
true
Dược Lực Học : Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA) indicated for the prophylaxis and chronic treatment of asthma. Patients with asthma were found in one study to be 25-100 times more sensitive to the bronchoconstricting activity of inhaled LTD4 than nonasthmatic subjects. In vitro studies demonstrated that zafirlukast antagonized the contractile activity of three leukotrienes (LTC4, LTD4 and LTE4) in conducting airway smooth muscle from laboratory animals and humans. Zafirlukast prevented intradermal LTD4-induced increases in cutaneous vascular permeability and inhibited inhaled LTD4-induced influx of eosinophils into animal lungs.
Cơ Chế Tác Dụng : Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.
Dược Động Học :
▧ Absorption :
Rapidly absorbed following oral administration, reduced following a high-fat or high-protein meal.
▧ Volume of Distribution :
* 70 L
▧ Protein binding :
99%
▧ Metabolism :
Hepatic
▧ Route of Elimination :
The most common metabolic products are hydroxylated metabolites which are excreted in the feces.
▧ Half Life :
10 hours
▧ Clearance :
* apparent oral CL=20 L/h * 11.4 L/h [7-11 yrs] * 9.2 L/h [5-6 yrs]
Độc Tính : Side effects include rash and upset stomach.
Chỉ Định : For the prophylaxis and chronic treatment of asthma.
Tương Tác Thuốc :
  • Acenocoumarol Zafirlukast may inhibit the metabolism of the vitamin K antagonist Acenocoumarol and increase INR and risk of bleeding.
  • Aminophylline Zafirlukast serum concentrations may be decreased by the theophylline derivative Aminophylline.
  • Capecitabine Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if capecitabine is initiated, discontinued or dose changed.
  • Cisapride Increased risk of cardiotoxicity and arrhythmias
  • Delavirdine Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if delavirdine is initiated, discontinued or dose changed.
  • Erythromycin Erythromycin may decrease the serum concentration and effect of zafirlukast.
  • Floxuridine Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if floxuridine is initiated, discontinued or dose changed.
  • Fluconazole Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluconazole is initiated, discontinued or dose changed.
  • Fluorouracil Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluorouracil is initiated, discontinued or dose changed.
  • Gemfibrozil Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if gemfibrozil is initiated, discontinued or dose changed.
  • Ketoconazole Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if ketoconazole is initiated, discontinued or dose changed.
  • Nicardipine Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if nicardipine is initiated, discontinued or dose changed.
  • Roflumilast Increases roflumilast levels.
  • Sitaxentan Sitaxentan, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sitaxentan is initiated, discontinued or dose changed.
  • Sulfadiazine Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfadiazine is initiated, discontinued or dose changed.
  • Sulfisoxazole Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfisoxazole is initiated, discontinued or dose changed.
  • Theophylline Zafirlukast serum concentrations may be decreased by Theophylline.
  • Tolbutamide Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if tolbutamide is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng : Tablet - Oral - 10 mg, 20 mg
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Accolate 20 mg tablet
    Giá bán buôn : USD >1.86
    Đơn vị tính : tablet
  • Biệt dược thương mại : Accolate 10 mg tablet
    Giá bán buôn : USD >1.92
    Đơn vị tính : tablet
Nhà Sản Xuất
  • Công ty : AstraZeneca
    Sản phẩm biệt dược : Accolate
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00549
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=5717
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506874
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C07206
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00411
ChemSpider
http://www.chemspider.com/Chemical-Structure.5515.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0310-0401-60
PharmGKB
http://www.pharmgkb.org/drug/PA451949
Wikipedia
http://en.wikipedia.org/wiki/Zafirlukast
RxList
http://www.rxlist.com/cgi/generic/zafirlukast.htm
Drugs.com
http://www.drugs.com/cdi/zafirlukast.html
... loading
... loading